An Adipokinetic Hormone Acts as a Volume Regulator in the Intertidal Gastropod Mollusk, *Aplysia californica*

Anthony W. Martillotti and Pei-San Tsai*

Department of Integrative Physiology, University of Colorado, Boulder, CO, United States

Adipokinetic hormone (AKH) is a multifunctional neuropeptide in the gonadotropin-releasing hormone superfamily. In insects, AKH acts to mobilize energy stores during times of high energetic demand, but has been shown to have other effects. In lophotrochozoans, the presence and function of AKH are less characterized. We have previously identified an AKH in an intertidal gastropod mollusk, the California sea hare (*Aplysia californica*), and named it ac-AKH. Our previous data showed ac-AKH induced an acute weight loss, suggesting a role in volume regulation. The overarching goals of this study were to test the role of ac-AKH as a volume regulator and examine the mechanism by which ac-AKH induced the acute weight loss. Our results showed that ac-AKH reduced body mass, in part, through the reduction of hemolymph volume without altering hemolymph osmolality or specific osmolytes. The effect of ac-AKH on volume loss was accentuated under a hyposaline condition. We further showed that *ac-akh* expression was inhibited during a hyposaline challenge, and that the administration of ac-AKH partially reversed the increase in body mass, but not hemolymph osmolality change, caused by the hyposaline challenge. These data collectively show that ac-AKH is a proximate regulator controlling the fluid volume, but not osmolality, in *A. californica*. Importantly, our results highlight the functional divergence of this structurally conserved neuropeptide in the molluscan lineage.

**Keywords:** adipokinetic hormone, osmoregulation, volume regulation, gonadotropin-releasing hormone superfamily, neuropeptide, neurohormone, evolution

**INTRODUCTION**

Adipokinetic hormone (AKH) is a small neuropeptide hormone and a member of the gonadotropin-releasing hormone superfamily. The presence and function of AKH are best characterized in the arthropods (1, 2). In insects, it is produced in the corpora cardiaca and chiefly released during times of high energetic demand to mobilize energy stores, including lipids, carbohydrates, and proteins (3–6). However, its function is not restricted to energetic balance. AKH also has a role in the stress response (7), and red pigment-concentrating hormone (RPCH), a crustacean homolog of insect AKH and a member of the AKH family (8, 9), mobilizes pigments and has a stimulatory effect on female reproduction (10). Therefore, AKH is considered a multifunctional neuropeptide capable of functions beyond the regulation of energetic balance.
We have previously characterized the structure and function of an AKH in a gastropod mollusk, *Aplysia californica* (11). The *A. californica* AKH (ac-AKH) was the first lophotrochozoan AKH to be characterized and showed several novel functions. While the chronic administration of ac-AKH resulted in increased hemolymph glucose, acute administration resulted in enhanced excretion of feces, inhibition of feeding, and a rapid loss of over 20% body mass within the first 6 h (11). The magnitude and rapid nature of the body mass loss induced by ac-AKH suggested the mechanism underlying this effect was water loss.

Osmoregulation and hemolymph volume regulation in gastropod mollusks are two poorly understood physiological processes. *A. californica* are intertidal animals that need to withstand substantial fluctuations in seawater salinity (12, 13), thus osmoregulation and volume regulation are critically required for their survival. Literature on this subject using the genus *Aplysia* is limited and typically focused on the electrophysiology of the burst neuron R15, a neuron in the abdominal ganglion thought to be involved in osmoregulation (14–19). One of the few studies on osmoregulation and volume regulation at the level of the organism (20) showed that *A. californica* transferred to a 90% artificial seawater (ASW) environment initially experienced reduced hemolymph osmolality and weight gain but later returned to their original osmolality and weight in 24 h, suggesting effective mechanisms of osmoregulation and hemolymph volume regulation within a salinity range. Based on our previous results that ac-AKH induced a rapid weight loss in *A. californica*, possibly through water loss (11), we hypothesized that ac-AKH may be involved in the processes of osmoregulation and volume regulation that allow the animals to cope with declining environmental salinity.

The objectives of this study were threefold. First, we determined if a single injection of ac-AKH altered the body mass and hemolymph osmolality of *A. californica* kept under different salinity conditions, and if the change in body mass was due, in part, to the change in hemolymph volume. Secondly, we determined if the transfer of *A. californica* from a normosaline to hyposaline condition altered the expression of ac-akh. Lastly, we treated the transferred animals with ac-AKH to determine if ac-AKH could reverse the weight gain induced by a normosaline to hyposaline transfer. Our results show, for the first time, the ability of an AKH to reduce hemolymph volume and reverse hyposaline-induced weight gain without a concurrent change in hemolymph osmolality. Further, the expression of ac-AKH was significantly reduced during a normosaline to hyposaline transfer when the animals gained water. Collectively, our results suggest ac-AKH has a physiological role in actively reducing body fluid content, and the reduced presence of this peptide may be needed for fluid gain. These results further highlight the functional diversity of the AKH peptide family and uncover a possible role of AKH in the molluscan lineage.

**MATERIALS AND METHODS**

**Animals**

Adult *A. californica* (between 92.2 and 216.6 g) were purchased from Alacrity Marine Biological Services (Redondo Beach, CA) or the National Resource for Aplysia (Miami, FL). Animals were housed individually in perforated floating cages in a recirculating system containing 300 gallons of Instant Ocean (Spectrum Brands, Blacksburg, VA) held at 15–18°C. All animals were acclimated to the experimental salinity for 48–72 h before use. Unless specified, all animals were anesthetized with 1/3 body mass of isotonic MgCl$_2$ immediately prior to sacrifice. For some experiments, animals were bled by quickly drawing hemolymph from the posterior foot using a 22-gauge needle at specified time points. Although institutional approval was not required for the use of *A. californica*, every effort was made to adhere to standards of humane treatment for the care and use of these animals.

**Experiment 1: Effects of ac-AKH Injection on Body Mass and Hemolymph Osmolality**

To assess the impact of ac-AKH on body mass and hemolymph osmolality under different salinity conditions, animals were acclimated to either a normosaline (997 mOsm/L) or a hyposaline (779 mOsm/L) environment. An osmolality of 997 mOsm/L is similar to oceanic osmolality (21), and 779 mOsm represents a 20% reduction. A baseline body mass was taken prior to a single injection of either 500 µL artificial seawater (ASW; 395 mM NaCl, 10 mM KCl, 10 mM CaCl$_2$, 50 mM MgCl$_2$, 28 mM Na$_2$SO$_4$, and 30 mM HEPES) or 10 µg ac-AKH in 500 µL ASW. The dose of injected ac-AKH was estimated to produce ~35-50 nM circulating peptide in the absence of protease degradation (11), a range consistent with the *in vivo* and *in vitro* treatments of many GnRH superfamily peptides (22–25). Animals were bled and additionally weighed at 1, 2, 4, 6, and 24 h after the injection. To assess the impact of ac-AKH on hemolymph osmolality, 500 µL of hemolymph was collected at 0, 6, and 24 h after the injection. Hemolymph was cleared by centrifugation at 3000 rpm and the supernatant stored at −20°C until osmolality measurement using a freezing-point depression osmometer. A fraction of hemolymph samples collected at 0 and 6 h were sent to Comparative Clinical Pathology Services, LLC (Columbia, MO) where ion-specific electrodes and commercial enzyme kits were used to assess concentrations of ions (Na$^+$, K$^+$, Cl$^-$, and Ca$^{2+}$), glucose, proteins, and triglycerides with a Beckman-Coulter AU680 automated chemistry analyzer (Brea, CA).

**Experiment 2: The Effects of ac-AKH on Hemolymph Volume**

To determine if weight loss induced by ac-AKH was due to a reduction in the hemolymph volume, terminal hemolymph volume was measured in animals injected with 500 µL ASW vehicle or 10 µg ac-AKH in 500 µL vehicle. For this experiment only, animals were anesthetized by a 30-min period of cold narcosis at 6 h after injection. Animals were firmly wrapped with a protective diaper to absorb contaminating mucus and ink and exsanguinated through a small opening made at the base of the foot by gentle manual squeezing. The entire hemolymph volume was collected into a beaker for future volume measurements. In our hands, animals never excrete mucus or ink after 30 min of cold narcosis. The standard procedure was followed to ensure all animals were bled until no more hemolymph could be collected after 90 s of repeated squeezing. Although the investigators were not blind to the treatment conditions, they were blind to the volume of the hemolymph collected until the
volume measurements were performed. Animals were weighed immediately prior to the injection and exsanguination.

**Experiment 3: Localization of ac-AKH in Peripheral and Central Tissues**

To examine the pattern of ac-AKH expression, tissues were collected from control animals previously injected with 500 μL ASW (from Experiment 1). The central nervous system (CNS), heart, kidney, gill, esophagus, crop, and intestine were harvested, snap-frozen on dry ice, and stored at −70°C until RNA isolation. Total RNA was isolated using TRIzol reagent (Ambion, Austin, TX) according to the manufacturer’s instructions. cDNA synthesis was performed from 1 μg total RNA using the Quantitect Reverse Transcription Kit (Qiagen, Germantown, MD) according to the manufacturer’s instructions. For quantitative reverse-transcription PCR (qPCR), *A. californica* actin (*ac-actin*) was used as a reference gene to normalize the target gene expression. qPCR primers for *ac-akh* were designed based on the previously published sequence (11). qPCR of *ac-akh* was carried out using FastStart Universal SYBR Green mix (Roche, Indianapolis, IN) and calculated using the 2−ΔΔCT method (26). Each reaction contained 9 μL SYBR Green mix, 9 μL ultrapure water, 0.5 μM gene-specific primers, and 2 μL (for *ac-actin* and *ac-akh*) of cDNA. Forward and reverse primers were 5′-CACACTGTCCCCATCTACGA and 5′-TCACAGTTCTGGGCA GGTATT for *ac-akh*.

**Experiment 4: Alteration of ac-AKH Expression During Normosaline to Hyposaline Transfer**

*A. californica* were transferred from a normosaline (1003 mOsm/L) to a hyposaline (757 mOsm/L) condition to determine the effects of salinity change on body mass and the expression of *ac-akh*. Animals were weighed at 1, 2, 4, and 6 h after the transfer and sacrificed at 6 h to harvest the hemolymph for osmolality measurement, and CNS, heart, kidney, and intestine for *ac-akh* transcript quantification by qPCR as described above for Experiment 3.

**Experiment 5: The Effects of ac-AKH on Hyposaline Transfer**

Since ac-AKH significantly reduced body mass in Experiment 1 under both salinity conditions, we assessed if ac-AKH injection could reverse the weight gain induced by transfer to a hyposaline condition. Animals were subjected to one of the following three treatments: (1) injected with 500 μL ASW vehicle and retained in a normosaline condition (984 mOsm/L), (2) injected with 500 μL ASW vehicle and transferred to a hyposaline condition (744 mOsm/L), or (3) injected with 10 μg ac-AKH in 500 μL vehicle and transferred to a hyposaline condition. Animals were weighed immediately before each hemolymph draw at 0, 0.5, 1, 2, 4, 6, and 8 h.

**Statistical Analysis**

Repeated measurements of changes in body mass and hemolymph parameters were analyzed using two-way repeated measures ANOVA followed by Bonferroni’s post-hoc test to determine significant difference between treatment groups at each time point. For Experiment 2, statistical analysis was not performed due to the descriptive nature of the expression profiling. Difference between two independent groups was otherwise analyzed by Student’s t-test with Welch’s correction.

**RESULTS**

**Experiment 1: Effects of ac-AKH Injection on Body Mass and Hemolymph Osmolality**

To examine the effects of ac-AKH on body mass and hemolymph osmolality, animals were kept under a normosaline or hyposaline condition, and their body mass measured at regular intervals. For animals kept under a normosaline condition, the initial mean body mass was 140.15 ± 4.20 g, and the initial mean hemolymph osmolality was 903.77 ± 22.04 mOsm/L. Two-way ANOVA revealed a significant effect of treatment (ac-AKH injection) [F(1, 65) = 5.482, p = 0.0391], but not time [F(5, 65) = 0.666, p = 0.6508] or treatment x time interaction [F(5, 65) = 1.699, p = 0.1502], on body mass (Figure 1A). Bonferroni’s post-hoc test revealed no significant differences between the treatment groups at any time point. For animals kept under a hyposaline condition, the initial mean body mass was 163.62 ± 8.29 g, and the initial mean hemolymph osmolality was 689.62 ± 10.11 mOsm/L. Two-way ANOVA revealed a significant effect of time [F(5, 65) = 14.76, p < 0.0001], treatment [F(1, 65) = 8.737, p = 0.0131], and treatment x time interaction [F(5, 65) = 2.385, p = 0.0475] on body mass was observed (Figure 1B). Bonferroni’s post-hoc test revealed that a single ac-AKH injection significantly reduced body mass at 4, 6, and 24 h under a hyposaline condition (Figure 1B). No significant differences in hemolymph osmolality were observed (Figures 1C,D). Additionally, no significant effects of ac-AKH on specific osmolyte concentrations were observed under the normosaline (Table 1) or hyposaline (Table 2) condition.

**Experiment 2: The Effects of ac-AKH on Hemolymph Quantity**

We hypothesized that the primary mechanism of ac-AKH induced acute weight loss in Experiment 1 was reduction of hemolymph volume. We tested this hypothesis by measuring the terminal hemolymph volume at 6 h after an ASW vehicle or ac-AKH injection. Two-way ANOVA revealed a significant effect of time [F(1, 14) = 26.92, p = 0.0002] and treatment x time interaction [F(1, 14) = 16.11, p = 0.0017] but not treatment [F(1, 14) = 3.511, p = 0.0855] on absolute body mass of animals injected with a single 10 μg dose of ac-AKH (Figure 2). Bonferroni’s post-hoc test revealed that treatment significantly reduced absolute mass at 6 h post-injection (Figure 2A). Student’s t-test revealed a significant reduction in absolute terminal hemolymph volume (Figure 2B) but no difference in absolute terminal hemolymph osmolality (Figure 2C) in animals injected with ac-AKH.
Experiment 3: Localization of ac-AKH in Peripheral and Central Tissues

qPCR was performed to examine the abundance and distribution of ac-AKH transcript in the CNS and peripheral tissues. Abundant ac-akh was observed in all central ganglia including the abdominal, buccal, cerebral, and pedal/pleural ganglia, and in two peripheral organs associated with osmoregulation, the intestine and the kidney. Low levels of ac-akh expression were detected in the remaining tissues examined (Figure 3).

Experiment 4: Alteration of ac-AKH Expression During Normosaline to Hyposaline Transfer

Since ac-AKH may be involved in fluid homeostasis, we tested if its expression could be altered by a change in salinity. Animals transferred from a normosaline to hyposaline condition showed a significant inhibition in ac-akh transcript exclusively in the abdominal ganglion after 6 h (Table 3). This change was accompanied by an increase in percent original body mass (99.99 ± 0.341% in retained vs. 118.13 ± 0.764% in transferred; \( p < 0.0001 \)) and a decrease in hemolymph osmolality in the transferred animals (970.13 ± 16.2 mOsm in retained vs. 851.63 ± 33.28 mOsm in transferred; \( p < 0.01 \)).

Experiment 5: The Effects of ac-AKH on Hyposaline Transfer

Since transfer to a hyposaline condition increased body mass in A. californica, we examined if ac-AKH could partially reverse the hyposalinity-induced weight gain. Two-way ANOVA revealed a significant effect of time \( [F(6, 90) = 40.8, p < 0.0001] \), treatment (from normo- to hypo-saline condition) \( [F(2, 90) = 42.67, p < 0.0001] \), and treatment x time interaction \( [F(6, 90) = 18.6, p < 0.0001] \) on body mass (Figure 4). Bonferroni’s post-hoc test revealed that the transfer to a hyposaline condition significantly
increased the body mass, but this increase was reversed by ac-AKH injection at 4, 6, and 8 h (Figure 4). Similarly, a time \( F(6, 90) = 257.7, p < 0.0001 \), treatment \( F(2, 90) = 52.66, p < 0.0001 \), and treatment x time interaction \( F(6, 90) = 45.18, p < 0.0001 \) had a significant effect on hemolymph osmolality. Bonferroni’s post-hoc test revealed that although the transfer to hyposaline condition significantly decreased hemolymph osmolality, in contrast to its ability to reverse the body mass gain, ac-AKH injection did not affect the decline in hemolymph osmolality (Figure 4).

**DISCUSSION**

For the first time, we report a potent effect of AKH treatment on the volume regulation in a marine gastropod mollusk, *A. californica*. We find that ac-AKH induces an acute volume loss while maintaining a hemolymph osmolality isotonic to the environment. Further, the hyposaline-induced downregulation of ac-akh in the abdominal ganglion, a ganglion responsible for key physiological functions such as reproduction, osmoregulation, circulation, and respiration (27), suggests ac-akh expression responds to the environmental salinity and the animal’s internal fluid volume and composition. Collectively, our results demonstrate a novel physiological role of an AKH in the lophotrochozoan lineage and emphasize the functional diversity of the AKH family.

We do not believe the volume regulating effect of ac-AKH is pharmacological for two reasons. First, animals previously injected with a higher dose of ac-AKH (15 µg/animal) exhibited no signs of desensitization and continued to respond to repeated injections for up to 20 days. Second, injection with a higher dose (30 µg/animal) of a related peptide [*A. californica* GnRH; Supplementary Table 1, (28–37)] did not induce weight loss, suggesting the effects of injected ac-AKH are not a general pharmacological response to an injected neuropeptide, but rather something specific and unique to ac-AKH (11).

The effect of ac-AKH on body mass reduction is stronger and longer-lasting under a hyposaline condition compared to a normosaline condition (Figures 1A,B). This suggests part of the physiological response to the hyposaline condition is increased responsiveness to ac-AKH. The mechanism for this sensitization is unclear, but may be related to a key osmoregulatory neuron in the abdominal ganglion, R15. R15 is a spontaneously bursting neuron that releases a presumptive hormone, R15x1, capable of increasing water retention (14–16, 38), an effect opposite to ac-AKH. Since the activity of R15 is inhibited under a hyposaline condition (17, 20), one possibility is that ac-AKH may synergize with the hyposaline condition to further inhibit R15, thereby leading to a greater volume loss.

We have confirmed that the ac-AKH-induced volume loss was due, in part, to the loss of hemolymph (Figure 2B). Previous and current studies have shown that a volume change induced by a hyposaline transfer was associated with a decrease in hemolymph osmolality for up to 6 h in *A. californica* and 24 h in *A. brasiliana* (16, 20), indicating volume disruption is typically coupled with a short-term hemolymph osmolality change. However, the present study shows that this is not the case for volume loss induced by injected ac-AKH. The mechanism by which ac-AKH induces volume loss while maintaining, in lockstep, the hemolymph

---

**TABLE 1** Effects of ac-AKH injection on hemolymph osmolyte concentrations under a normosaline condition.

| Osmolyte         | ASW 0 h (mEq/L) | ASW 6 h (mEq/L) | AKH 0 h (mEq/L) | AKH 6 h (mEq/L) | p-value     |
|------------------|-----------------|----------------|----------------|----------------|-------------|
| Na⁺              | 472.9 ± 4.557   | 468.2 ± 8.032  | 464 ± 4.888    | 467.5 ± 12.21  | Not significant |
| K⁺               | 11.48 ± 0.807   | 11.38 ± 0.2188 | 11.22 ± 0.1158 | 11.4 ± 0.6696  | Not significant |
| Cl⁻              | 536.6 ± 5.19    | 525.8 ± 5.31   | 531 ± 9.227    | 531.1 ± 14.76  | Not significant |
| Ca²⁺ (g/dL)      | 45.33 ± 0.2611  | 45.15 ± 1.868  | 44.72 ± 0.2893 | 45.13 ± 1.237  | Not significant |
| Glucose (mg/dL)  | 2.8 ± 0.8       | 2.8 ± 0.6633   | 2.2 ± 0.3742   | 2.8 ± 0.4899   | Not significant |
| Proteins (mg/dL) | 62.4 ± 6.265    | 60.2 ± 13.9    | 70 ± 11.06     | 71.8 ± 8.423   | Not significant |
| Triglycerides (mg/dL) | Not detected | Not detected | Not detected | Not detected | N/A |

Concentrations are reported as the mean ± SEM, n = 5. No significant differences were observed.

**TABLE 2** Effects of ac-AKH injection on hemolymph osmolyte concentrations under a hyposaline condition.

| Osmolyte         | ASW 0 h (mEq/L) | ASW 6 h (mEq/L) | AKH 0 h (mEq/L) | AKH 6 h (mEq/L) | p-value     |
|------------------|-----------------|----------------|----------------|----------------|-------------|
| Na⁺              | 364.7 ± 23.57   | 320.5 ± 7.243  | 352.7 ± 2.221  | 344.4 ± 9.555  | Not significant |
| K⁺               | 9.028 ± 0.6398  | 7.988 ± 0.171  | 8.562 ± 0.06492| 8.356 ± 0.2181 | Not significant |
| Cl⁻              | 412.5 ± 26.34   | 361.8 ± 8.08   | 396 ± 2.525    | 389 ± 10.43    | Not significant |
| Ca²⁺ (g/dL)      | 35.14 ± 2.31    | 34.34 ± 0.3811 | 30.68 ± 0.7106 | 32.49 ± 1.296  | Not significant |
| Glucose (mg/dL)  | 3.2 ± 0.4989    | 2.6 ± 0.4      | 3.6 ± 0.2449   | 3.4 ± 0.4      | Not significant |
| Proteins (mg/dL) | 85.2 ± 14.71    | 69.4 ± 10.47   | 83 ± 2.646     | 69 ± 10.63     | Not significant |
| Triglycerides (mg/dL) | Not detected | Not detected | Not detected | Not detected | N/A |

Concentrations are reported as the mean ± SEM, n = 4-5. No significant differences were observed.
Martillotti and Tsai

**FIGURE 2** | Change in absolute body mass (A), terminal hemolymph volume (B), and terminal hemolymph osmolality (C) in response to a single injection of ASW vehicle or 10 µg ac-AKH 6 h prior to sacrifice. Each data point and bar for (A,B) represents mean ± SEM, n = 7, and each bar for (C) represents mean ± SEM, n = 6. For (A), a two-way ANOVA revealed a significant effect of time, but not treatment, on body mass (*** denotes p < 0.001). A significant difference in body mass between groups at 6 h was observed (## denotes p < 0.01). For (B), Student’s t-test measured a significant difference in terminal hemolymph volume between groups (** denotes p < 0.01). For (C), Student’s t-test measured no significant difference in terminal hemolymph osmolality.

osmolality and osmolyte concentrations identical to those of control animals is at present unclear. We posit that ac-AKH induces volume loss without disrupting hemolymph osmolality by promoting the excretion of fluid isotonic to hemolymph. The mechanism underlying this type of fluid loss remains to be explored.

The distribution of ac-akh (Figure 3) further supports the hypothesis that ac-AKH is involved in volume regulation. We have previously localized the ac-AKH peptide in the abdominal, cerebral, and pleural ganglia (11), thus the expression of ac-akh in these ganglia is expected. We have also shown elevated expression of ac-akh in the intestine, an osmoregulatory tissue (39–41), a result consistent with the previous observation that ac-AKH-induced defection in A. californica, possibly by altering gut motility (11). Finally, we find higher levels of expression of ac-akh in the kidney, a tissue associated with osmoregulation and volume regulation in vertebrates (42) and A. californica (43). However, the expression of ac-akh in the gill, a tissue associated with osmoregulation in teleost fishes (44) and A. californica (27), is very low (Figure 3). Overall, the expression pattern of ac-akh in the periphery supports the role of ac-AKH as a volume regulator.

We have previously found no evidence of ac-AKH immunoreactive cells in the periphery (11), suggesting peripheral tissues do not have the capability of de novo ac-AKH synthesis. We therefore hypothesize that the ac-akh transcript presently detected in the peripheral organs (Figure 2) represents mRNA transported to and stored in the axon terminals of the target organs and locally translated at levels below detection (45). This suggests ac-AKH may act as a neurotransmitter/neuromodulator, a role previously shown in crustaceans for a member of the AKH family, RPCH (10, 46) to influence its targets. Supporting this notion, ac-AKH immunoreactivity is not present in R15 but found in a few smaller unidentified neurons and abundant fibers impinging on multiple abdominal ganglion neurons and in
the neuropil region of the CNS (11). Since the neuropil region concentrates efferent fibers, it is possible that ac-AKH acts as a neurotransmitter/neuromodulator to influence the activity of R15 and peripheral targets to promote fluid loss. Alternatively, a change in the endogenous burst activity of R15 may influence the transcription of ac-akh, leading to the altered control of peripheral targets.

We additionally show that a hyposaline transfer induces a downregulation of ac-akh in the abdominal ganglion (Table 3). This would be counterintuitive for an adaptive osmoregulatory response to a hyposaline challenge since ac-AKH promotes fluid loss, but would be consistent with a volume gain during a hyposaline transfer if the animal behaves as an osmoconformer. Although Skinner and Peretz (1989) showed that A. californica could act as an osmoregulator by achieving a full recovery of hemolymph osmolality and body mass 24 h after being transferred to 90% oceanic salinity, our current data suggest that A. californica become an osmoconformer in a more dilute environment of 80% oceanic salinity, possibly as an adaptive strategy to conserve energy. This shift between osmoregulation and osmoconformation is also observed in another intertidal Aplysia species, A. juliana, which behave as an osmoregulator under a slightly hyposaline environment but an osmoconformer under a more dilute environment (43). In this sense, ac-AKH may not be a peptide that maintains homeostasis by promoting osmoregulation, but rather one that aids in the transition to osmoconformation. A. californica is an intertidal species that needs to withstand substantial salinity changes. For example, A. californica stranded in a small tide pool experience more extreme fluctuations in environmental salinity due to rainfall or evaporation (13). Changes in ac-AKH levels may allow A. californica to gain or lose fluid so its internal osmolality conforms with the environmental osmolality. Ultimately, our data suggest that ac-AKH likely has an important role in volume regulation but not necessarily osmoregulation.

We show that the administration of ac-AKH is capable of partially reversing the body mass gain following a hyposaline transfer (Figure 4). Since ac-akh is downregulated by a hyposaline challenge, we posit that ac-AKH has a physiological role in promoting a constitutive fluid loss, and the weight gain resulting from a hyposaline challenge is at least in part a consequence of decreased ac-AKH. In other words, reduced ac-AKH is needed for the animal to gain volume. This reversal of

![FIGURE 3 | Relative expression of ac-akh in the pedal and pleural ganglia (P/P), the abdominal ganglion (Abd), the buccal ganglion (Buc), the cerebral ganglion (Cer), the heart (Hrt), the gill (Gill), the intestine (Int), the esophagus (Esp), the crop (Crp), and the kidney (Kid). Each bar represents mean ± SEM, n = 5. Statistical analysis was not performed for this study.]

| Tissue                  | 2^−ΔACT Retained | 2^−ΔACT Transferred | p-value |
|-------------------------|-------------------|---------------------|---------|
| Abdominal Ganglion      | 1.022 ± 0.1014    | 0.564 ± 0.08047    | 0.0083  |
| Buccal Ganglion         | 1.26 ± 0.3214     | 2.802 ± 1.443      | Not significant |
| Cerebral Ganglion       | 1.172 ± 0.2638    | 0.808 ± 0.1509     | Not significant |
| Pedal/Pleural Ganglion  | 1.02 ± 0.1206     | 0.764 ± 0.1071     | Not significant |
| Heart                   | 2.168 ± 1.138     | 1.678 ± 0.655      | Not significant |
| Intestine               | 3.232 ± 2.444     | 1.18 ± 0.3068      | Not significant |
| Kidney                  | 1.408 ± 0.4525    | 1.983 ± 0.5262     | Not significant |

Each value represents mean ± SEM, n = 4–5. Student’s t-test showed a significant reduction in ac-akh transcript in the abdominal ganglion only.
FIGURE 4 | Percent change in (A) body mass or (B) hemolymph osmolality in A. californica either retained in a normosaline condition and injected with ASW vehicle, transferred to a hyposaline condition and injected with ASW, or transferred to a hyposaline condition and injected with 10 µg ac-AKH. Each data point represents mean ± SEM, n = 5. Vertical and horizontal bars indicate a significant effect of treatment and time, respectively, measured by a two-way ANOVA (**** denotes p < 0.0001). For (A), significant differences were observed at several time points between the retained group and both transferred groups (### denotes p < 0.0001), and between the ASW-injected transfer group and the ac-AKH-injected transfer group († denotes p < 0.05, †††† denotes p < 0.0001). For (B), significant differences were observed at several time points between the retained group and the transferred groups (#### denotes p < 0.0001), but not between the two transferred groups.

the body mass gain induced by ac-AKH is, again, not coupled to osmoregulation. In vertebrates, hormone-induced volume regulation and osmoregulation are closely linked (47, 48), but the current study shows that ac-AKH affects hemolymph volume without significantly altering hemolymph osmolality or specific osmolytes.
The discovery of AKH members in the lophotrochozoan lineage is relatively new (2), and they are currently neuropeptides in search of a function. Our results show, for the first time, that a lophotrochozoan AKH acts as a volume regulator without altering the hemolymph osmolality. We also show that this effect of ac-AKH is accentuated under a hyposaline condition, the expression of ac-AKH is inhibited under a hyposaline condition, and the administration of ac-AKH is capable of partially reversing the increase in body mass, but not a decline in hemolymph osmolality, induced by a hyposaline transfer. Collectively, these data underscore a novel mechanism of volume regulation induced by ac-AKH. Further, they suggest a need to explore a role of AKH in volume and osmoregulation among additional members of the lophotrochozoan lineage.

ETHICS STATEMENT

As Aplysia californica are invertebrate animals, the approval of IACUC was not required. However, every effort was made to adhere to humane standards of treatment for care and use of these animals.

REFERENCES

1. Gäde G. Peptides of the adipokinetic hormone/red pigment-concentrating hormone family. Ann N Y Acad Sci. (2009) 1163:125–36. doi: 10.1111/j.1749-6632.2008.03625.x
2. Hauser F, Grimmelikhuijzen CJP. Evolution of the AKH/corazonin/ACP/GnRH receptor superfamily and their ligands in the Protostomia. Gen Comp Endocrinol. (2014) 209:35–49. doi: 10.1016/j.ygcen.2014.07.009
3. Schooneveld H, Tesser IG, Veenstra JA, Romberg-Privee HM. Adipokinetic hormone and AKH-like peptide demonstrated in the corpora cardiaca and nervous system of Locusta migratoria by immunocytochemistry. Cell Tissue Res. (1983) 230:67–76. doi: 10.1007/BF00216028
4. Gäde G, Auerswald L. Insect neuropeptides regulating substrate mobilisation. South Afr J Zool. (1998) 33:2.
5. Gäde G, Auerswald L. Mode of action of neuropeptides from the adipokinetic hormone family. Gen Comp Endocrinol. (2003) 132:10–20. doi: 10.1016/S0016-6480(03)00159-X
6. Van der Horst DJ. Insect adipokinetic hormones: release and integration of flight energy metabolism. Comp Biochem Physiol Part B. (2003) 136:217–26. doi: 10.1016/S1096-4959(03)00151-9
7. Kodrik D. Adipokinetic hormone functions that are not associated with insect flight. Physiol Entomol. (2008) 33:171–80. doi: 10.1111/j.1365-3032.2008.00625.x
8. Gäde G. The adipokinetic hormone/red pigment-concentrating hormone peptide family: Structures, interrelationships and functions. J Insect Physiol. (1990) 36:1–12.
9. Gäde G. The revolution in insect neuropeptides illustrated by the adipokinetic hormone/red-pigment-concentrating hormone family of peptides. Zeitschrift für Naturforschung (1996) 51:607–17.
10. Sarojini R, Nagabhushanam R, Fingerman M. A neurotransmitter role for red-pigment-concentrating hormone in ovarian maturation in the red swamp crayfish Procambarus clarkii. J Exp Biol. (1995) 198:1253–7.
11. Johnson JL, Kavanaugh SL, Nguyen C, Tsai P-S. Localization and functional characterization of a novel adipokinetic hormone in the Mollusk, Aplysia californica. PLoS ONE (2014) 9:e106014. doi: 10.1371/journal.pone.0106014
12. Carefoot TH. Aplysia: its biology and ecology. Oceanogr Mar Biol Ann Rev. (1987) 25:167–84.

AUTHOR CONTRIBUTIONS

AM and P-ST conceived and designed the experiments. AM performed the experiments and statistical analysis. AM and P-ST wrote and revised the manuscript.

FUNDING

Experiments were supported by NSF Grant IOS 1352944 to P-ST.

ACKNOWLEDGMENTS

The authors would like to thank Arrianna Díaz and Michaela Deck for their assistance in data collection and animal care, and Nate Anderson for his assistance with aquarium assembly and maintenance.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2018.00493/full#supplementary-material
24. Porter DA, Licht P. Pituitary responsiveness to superfused GnRH in two species of ranid frogs. Gen Comparat Endocrinol. (1985) 59:308–15. doi: 10.1016/0014-5793(85)90383-1

25. Connolly PB, Callard IP. Luteinizing hormone secretion from the quail pituitary in vitro. Biol Reprod. (1987) 36:1238–46. doi: 10.1095/biolreprod.36.5.1238

26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods (2001) 25:402–8. doi: 10.1016/meth.2001.1262

27. Kandel ER, Schwartz JH, Jessell TM, Siegelbaum SA, Hudspeth AJ. Principles of Neural Science. 5 Ed. New York City, NY: McGraw-Hill (2013).

28. Stone JV, Mordue W, Batley KE, Morris HR. Structure of locust adipokine: aminopeptidase from the American cockroach. J Biol Chem. (2001) 276:17717–3. doi: 10.1126/science.1044.173

29. Witten JL, Schaffer MH, O'Shea M, Cook JC, Hemling ME, Rinehart KL. Structures of two cockroach neuropeptides assigned by fast atom bombardment mass spectrometry. Biochem Biophys Res Commun. (1984) 124:350–8. doi: 10.1016/0006-291X(84)91560-2

30. Scarborough RM, Jamieson GC, Kalish F, Kramer SJ, McEnroe GA, Miller CA, et al. Isolation and primary structure of two peptides with cardioacceleratory and hyperglycemic activity from the corpora cardiaca of Periplaneta americana. Proc Natl Acad Sci USA. (1984) 81:5575–9. doi: 10.1073/pnas.81.17.5575

31. Marco HG, Smek P, Clark KD, Gade G. Novel adipokinetic hormones in the kissing bugs Rhodnius prolixus, Triatoma infestans, Dipetalogaster maxima and Panstrongylus megistus. Peptides (2013) 41:21–30. doi: 10.1016/j.peptides.2012.09.032

32. Fernlund P, Jøføsslon L. Crustacean color-change hormone: amino acid sequence and chemical synthesis. Science (1972) 177:173–5. doi: 10.1126/science.177.4044.173

33. Hansen KK, Stafflinger E, Schneider M, Hauser F, Cazzamali G, Williamson M, et al. Discovery of a novel insect neuropeptide signaling system closely related to the insect adipokinetic hormone and corazonin hormonal system. J Biol Chem. (2010) 285:10736–47. doi: 10.1074/jbc.M109.045369

34. Veenstra JA. Isolation and structure of corazonin, a cardioactive peptide from the American cockroach. FEBS Lett. (1989) 250:231–4. doi: 10.1016/0014-5793(89)80727-6

35. Sun B, Kavanaugh SI, Tsai P-S. Gonadotropin-releasing hormone in protostomes: insights from functional studies on Aplysia californica. Gen Comparat Endocrinol. (2012) 176:321–6. doi: 10.1016/j.ygenen.2011.11.030

36. Miyamoto K, Hasegawa Y, Nomura M, Igarashi M, Kangawa K, Matsuo H. Identification of the second gonadotropin-releasing hormone in chicken hypophalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species. Proc Natl Acad Sci USA. (1984) 81:3874–8. doi: 10.1073/pnas.81.12.3874

37. Sherwood N, Elden L, Brownstein M, Spiess J, Rivier J, Vale W. Characterization of a teleost gonadotropin-releasing hormone. Proc Natl Acad Sci USA. (1983) 80:2794–8. doi: 10.1073/pnas.80.9.2794

38. Weiss KR, Bayley H, Lloyd PE, Tenenbaum R, Kolks MA, Buck L, et al. Purification and sequencing of neuropeptides contained in neuron R15 of Aplysia californica. Proc Natl Acad Sci USA. (1989) 86:2913–7. doi: 10.1073/pnas.86.8.2913

39. Gerencser GA. Na+ absorption in Aplysia intestine: Na+ fluxes and intracellular Na+ and K+ activities. Regulatory, Integr Comp Physiol. (1983) 244:R412–7. doi: 10.1152/ajpregu.1983.244.3.R412

40. Kirsch R, Humbert W, Simonneaux V. The gut as an osmoregulatory organ: comparative aspects and special references to fishes. In: Gilles R, Gilles-Bailhlien M eds. Transport Processes, Iono- and Osmoregulation. Proceedings in Life Sciences. Berlin:Heidelberg: Springer (1985). p. 265–77.

41. Grosell M. Intestinal anion exchange in marine fish osmoregulation. J Exp Biol. (2006) 209:2813–27. doi: 10.1242/jeb.02345

42. Bourque CW. Central mechanisms of osmosensation and systemic osmoregulation. Nat Rev Neurosci. (2008) 9:519. doi: 10.1038/nrn2400

43. van Weel PB. Observations on the osmoregulation in Aplysia juliana Pease (Aplysiidae, Mollusca), Zeitschrift für vergleichende Physiologie (1957) 39:492–506.

44. Evans DH, Piermarini PM, Choe KP. The multifunctional fish gill: dominant site of gas exchange, osmoregulation, acid-base regulation, and excretion of nitrogenous waste. Physiol Rev. (2005) 85:97–177. doi: 10.1152/physrev.00150.2003

45. Mohr E, Richter D. Axonal mRNAs: functional significance in vertebrates and invertebrates. J Neurocytol. (2000) 29:783–91. doi: 10.1023/A:1010987206526

46. Rao KR, Riehm JP. Pigment-dispersing hormones. Ann N Y Acad Sci. (1993) 680:78–88. doi: 10.1111/j.1749-6632.1993.tb19676.x

47. McCormick SD. Endocrine control of osmoregulation in teleost fish. Am Zool. (2001) 41:781–94. doi: 10.1093/icb/41.4.781

48. McCormick SD, Bradshaw D. Hormonal control of salt and water balance in vertebrates. Gen Comparat Endocrinol. (2006) 147:3–8. doi: 10.1016/j.ygenen.2005.12.009

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Martillotti and Tsai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.